Eli Lilly's experimental 'triple-G' drug retatrutide has delivered weight loss results in late-stage trials, but questions remain about its effect on cardiovascular outcomes, according to data released by the company.
Average weight loss achieved by patients taking retatrutide across late-stage trials.
Retatrutide is a triple agonist—meaning it targets three gut hormone pathways simultaneously—and Eli Lilly is positioning it as the next pillar of its obesity portfolio. The company has said it will file for regulatory approval in 2027.
Eli Lilly is positioning retatrutide as the next pillar of its obesity portfolio.
However, the drug did not show a statistically significant reduction in the risk of death, heart attack, or stroke in secondary endpoints, according to the data. Some trial reports have highlighted positive results and filing plans but did not mention this lack of significant cardiovascular benefit.
The company has reported positive results from five late-stage trials on retatrutide, though some accounts mention only two additional Phase 3 trials beyond the main readout. The discrepancy reflects differing emphasis in reporting, not conflicting data.
